Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SSY Group ( (HK:2005) ) has shared an announcement.
SSY Group Limited has announced that its product, Allopurinol, has received approval from the National Medical Products Administration of China to be marketed as a bulk drug. This development marks a significant step in the company’s product offerings, particularly in the treatment of gout and high uric acid, potentially enhancing its position in the pharmaceutical market.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of medical products. The company is involved in creating treatments for various health conditions, with a market focus on pharmaceuticals.
YTD Price Performance: -10.39%
Technical Sentiment Signal: Buy
Current Market Cap: $1.15B
For an in-depth examination of 2005 stock, go to TipRanks’ Stock Analysis page.